Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

December 27, 2019 00:23:35
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?
Critical Care Perspectives in Emergency Medicine
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

Dec 27 2019 | 00:23:35

/

Show Notes

Up to one-third of patients with status epilepticus will not respond to benzodiazepines.  Unfortunately, treatment of benzodiazepine-refractory status epilepticus is not well studied.  The longer seizures persist, the worse patients do.  In this podcast, we discuss the results of the recently completed ESETT trial that evaluated three anticonvulsant medications for status epilepticus.

You can get CME credit for this episode here!Click here for CME Account Creation Instructions

Other Episodes

Episode 0

November 23, 2020 00:41:34
Episode Cover

2020 AHA Guidelines for Cardiopulmonary Resuscitation

Approximately 350,000 adults in the US experience an out-of-hospital cardiac arrest (OHCA).  Despite numerous potential improvements in treatments, survival from OHCA remains essentially unchanged...

Listen

Episode 0

May 19, 2022 00:22:48
Episode Cover

Refractory OHCA - Does ECPR and Early Angiography Improve Outcome?

In a recent podcast we reviewed the ARREST Trial, which demonstrated significant improvement in survival among OHCA patients at a single center randomized to...

Listen

Episode 0

June 24, 2019 00:26:09
Episode Cover

Anticoagulation Reversal for ICH

ICH accounts for approximately 15 percent of all strokes.  Despite improvements in neurocritical care, the mortality for patients with ICH can still reach 50...

Listen